H.R. 1691 118th Congress
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
- Health
- Sponsor: Rep. Wenstrup, Brad R. [R-OH-2]
- Congress.gov ↗
Latest action, Dec 24, 2024: Placed on the Union Calendar, Calendar No. 801.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
89 cosponsors
Sponsored by Rep. Wenstrup, Brad R. [R-OH-2] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
44 D · 45 R
- Democrat
- Republican
- Independent
Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
8 reports
8 reports
LIFE SCIENCES PENNSYLVANIA
8 reports
MEDICAL ALLEY ASSOCIATION
THE PETRIZZO GROUP, INC.
8 reports
MEDICAL DEVICE MANUFACTURERS ASSOCIATION
THE MCMANUS GROUP
8 reports
8 reports
8 reports
8 reports
8 reports
7 reports
7 reports
CALIFORNIA LIFE SCIENCES
W STRATEGIES, LLC
7 reports
MEDTRONIC, INC.
W STRATEGIES, LLC
7 reports
All 25 of 52 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| BOSTON SCIENTIFIC CORPORATION | 8 | $3.0M | Q1 2023 | Q3 2024 | yes | |
| EDWARDS LIFESCIENCES LLC | 8 | $3.1M | Q1 2023 | Q3 2024 | yes | |
| LIFE SCIENCES PENNSYLVANIA | 8 | $29K | Q1 2023 | Q3 2024 | yes | |
| MEDICAL ALLEY ASSOCIATION | THE PETRIZZO GROUP, INC. | 8 | $280K | Q1 2023 | Q3 2024 | yes |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | 8 | $2.4M | Q1 2023 | Q3 2024 | yes | |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | THE MCMANUS GROUP | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| MEDTRONIC INC | 8 | $8.1M | Q1 2023 | Q3 2024 | yes | |
| NATIONAL VENTURE CAPITAL ASSOCIATION | 8 | $5.0M | Q1 2023 | Q3 2024 | yes | |
| NOVOCURE INC. | 8 | $1.2M | Q1 2023 | Q3 2024 | yes | |
| THE COOK GROUP INC. | 8 | $1.1M | Q1 2023 | Q3 2024 | yes | |
| ABIOMED, INC | 7 | $1.1M | Q1 2023 | Q3 2024 | yes | |
| ADVANCED MEDICAL TECHNOLOGY ASSN | 7 | $5.9M | Q4 2023 | Q3 2024 | yes | |
| CALIFORNIA LIFE SCIENCES | W STRATEGIES, LLC | 7 | $0 | Q4 2023 | Q3 2024 | — |
| F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES | 7 | $870K | Q4 2023 | Q3 2024 | yes | |
| MEDTRONIC, INC. | W STRATEGIES, LLC | 7 | $0 | Q4 2023 | Q3 2024 | — |
| PHILIPS HOLDING USA INC. | 7 | $4.0M | Q4 2023 | Q3 2024 | yes | |
| REFLEXION MEDICAL | KOUNTOUPES DENHAM CARR & REID, LLC | 7 | $420K | Q4 2023 | Q3 2024 | yes |
| ADVAMED:ADVANCED MEDICAL TECHNOLOGY ASSOCIATION | EMERGENT STRATEGIES | 6 | $270K | Q4 2023 | Q3 2024 | yes |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) | CAPITOL COUNSEL LLC | 6 | $300K | Q4 2023 | Q3 2024 | yes |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) | CROSSROADS STRATEGIES, LLC | 6 | $300K | Q4 2023 | Q3 2024 | yes |
| HENRY SCHEIN | MEHLMAN CONSULTING, INC. | 6 | $300K | Q4 2023 | Q3 2024 | yes |
| MASSMEDIC | ML STRATEGIES, LLC | 6 | $120K | Q4 2023 | Q3 2024 | yes |
| ZIMMER BIOMET | THE MCMANUS GROUP | 6 | $0 | Q4 2023 | Q3 2024 | yes |
| CURE SMA | 5 | $375K | Q4 2023 | Q3 2024 | yes | |
| ROCHE DIAGNOSTICS CORPORATION | HOOPER, LUNDY & BOOKMAN, P.C. | 5 | $150K | Q4 2023 | Q3 2024 | yes |